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The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding
potential benefits of supporting early, rather than delayed, peanut introduction during the period of
complementary food ntroduction in infants. This document should be considered as interim guidance based
on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology;
American Academy of Pediatrics; American College of Allergy, Asthma & Immunology; Australasian Society of
Clinical Immunology and Allergy; Canadian Society of Allergy and Clinical Immunology; European Academy of
Allergy and Clinical Immunology; Israel Association of Allergy and Clinical Immunology; Japanese Society for
Allergology; Society for Pediatric Dermatology; and World Allergy Organization. More formal guidelines
regarding early-life, complementary feeding practices and the risk of allergy development will follow in the
next year from the National Institute of Allergy and Infectious Diseases – sponsored Working Group and the
European Academy of Allergy and Clinical Immunology.
Keywords: Allergy prevention, Complementary feeding, Peanut allergyIntroduction and rationale
Peanut allergy is an increasingly troubling global health
problem affecting between 1 % and 3 % of children in
many westernized countries. Although multiple methods of
measurement have been used and specific estimates differ,
there appears to be a sudden increase in the number of
cases in the past 10- to 15-year period, suggesting that the
prevalence might have tripled in some countries, such as
the United States. Extrapolating the currently estimated
prevalence, this translates to nearly 100,000 new cases an-
nually (in the United States and United Kingdom), affecting
some 1 in 50 primary school-aged children in the United
States, Canada, the United Kingdom, and Australia. A
similar rise in incidence is now being noted in developing
countries, such as Ghana [1–6].* Correspondence: echan5@cw.bc.ca
†Each contributed equally to this work as Primary Contributors
5Canadian Society of Allergy and Clinical Immunology (CSACI), Vancouver,
BC, Canada
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Dedication waiver (http://creativecommons
article, unless otherwise stateThe purpose of this brief communication is to high-
light emerging evidence for existing allergy prevention
guidelines regarding potential benefits of supporting
early rather than delayed peanut introduction during the
period of complementary food introduction in infants. A
recent study, entitled “Randomized trial of peanut con-
sumption in infants at risk for peanut allergy” demon-
strated a successful 11 % to 25 % absolute reduction in
the risk of peanut allergy in high-risk infants (and a rela-
tive risk reduction of up to 80 %) if peanut was intro-
duced between 4 and 11 months of age [7]. In light of
the significance of these findings, this document serves
to better inform the decision-making process for health-
care providers regarding such potential benefits of early
peanut introduction. More formal guidelines regarding
early-life, complementary feeding practices and the risk
of allergy development will follow in the next year from
the National Institute of Allergy and Infectious Diseases
(NIAID)-sponsored Working Group and the European
Academy of Allergy and Clinical Immunology (EAACI),icle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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guidance.
Summary of new evidence
In the Learning Early About Peanut Allergy (LEAP) trial,
640 high-risk United Kingdom infants (See Box 1) be-
tween the ages of 4 to 11 months were randomized to
consume peanut products at least three times a week
(6 g of peanut protein; equivalent to 24 g peanuts or 3
teaspoons of peanut butter per week) or to completely
avoid peanut products for the first 5 years of life. This
included 542 infants found to have negative skin prick
test (SPT) responses to peanut at study entry, and 98 in-
fants with SPT wheal diameters to peanut of between 1
and 4 mm (minimally positive SPT response) at study
entry. An additional 76 children were excluded from study
entry before randomization based on an SPT response of
greater than 5 mm, which was assumed to result in a very
high likelihood of reacting to a peanut challenge. In an
intention-to-treat analysis, 17.2 % in the peanut avoidance
group compared to 3.2 % in the peanut consumption
group had food challenge-proved peanut allergy by age
5 years, corresponding to a 14 % absolute risk reduction, a
number needed to treat (NNT, eg, number of persons
needed to be treated for one to receive benefit) of 7.1, and
a relative risk reduction of 81 % [7].
When examined in further detail, the isolated benefi-
cial effects for both the primary and secondary preven-
tion of peanut allergy translated to an NNT of 8.5
among the infants with negative SPT responses and an
NNT of 4 among the infants with minimally positive
SPT responses. Secondary analyses also showed similar
levels of prevention in white, black and Asian (Indian
and Pakistani) children. Overall, the risk of early intro-
duction in this group was low: 7 of the 319 children ran-
domized to the consumption group reacted to peanut at
the baseline food challenge, suggesting that peanut food
challenges and introduction, even in infants with minim-
ally positive SPT responses, are safe and feasible. Six
children in the consumption group had peanut allergy
during the study, indicating that peanut allergy can still
develop despite attempts at primary and secondary pre-
vention. Finally, the LEAP trial only included high-risk
infants with a minimal or negative SPT response to pea-
nut and therefore does not address a strategy for those
without these risk factors for peanut allergy [7].
How does the LEAP trial affect present guidance
for early complementary feeding practices?
Existing guidelines pertaining to the early introduction
of complementary foods have indicated that the intro-
duction of highly allergenic foods, such as peanut,
need not be delayed past 4 or 6 months of life. How-
ever, they do not actively recommend introduction ofpeanut between 4 and 6 months of age in high-risk in-
fants, and some of these guidelines specify that certain
infants considered at high risk for allergic disease are
recommended to first consult an expert [8–14].
The LEAP data provide Level 1 evidence that the
practice of early peanut introduction is safe and effect-
ive in selected high-risk infants. This study is the first
prospective, randomized trial of early peanut interven-
tion and informs provider decision-making regarding
high-risk infants, including those already having a
positive peanut SPT response but not yet clinically reactive,
to receive the benefits noted in the LEAP trial, which
might reduce the risk of peanut allergy up to 80 %.
Of note, since children with lesser risk factors for
peanut allergy were excluded from enrollment in the
LEAP trial, there are no prospective, randomized data
investigating the benefit or risk of early peanut intro-
duction in the general to low-risk populations. Conse-
quently, this communication’s guidance is limited to
applying the findings of the LEAP trial to other similar
high-risk children in more diverse settings around the
world. However, multiple guidelines have not recom-
mended delaying allergen introduction in the general
to low-risk populations.
Interim guidance regarding early peanut
introduction
Based on data generated in the LEAP trial and existing
guidelines, the following interim guidance is suggested
to assist the clinical decision-making of health care
providers:
 There is now scientific evidence (Level 1 evidence
from a randomized controlled trial) that
healthcare providers should recommend
introducing peanut-containing products into the
diets of “high-risk” infants early on in life (between
4 and 11 months of age) in countries where peanut
allergy is prevalent because delaying the introduction
of peanut can be associated with an increased risk of
peanut allergy.
 Infants with early-onset atopic disease, such as
severe eczema, or egg allergy in the first 4 to
6 months of life (see Box 1 for example LEAP
criteria), might benefit from evaluation by an allergist
or physician trained in management of allergic diseases
in this age group to diagnose any food allergy and assist
in implementing these suggestions regarding the appro-
priateness of early peanut introduction. Evaluation of
such patients might consist of performing peanut skin
testing, in-office observed peanut ingestion, or both, as
deemed appropriate after discussion with the family.
The clinician can perform an observed peanut
challenge for those with evidence of a positive
Box 2 Examples of Peanut-containing Foods Utilized
in the LEAP Trial
• Smooth peanut butter (1 teaspoon) mixed with milk or with
mashed or pureed fruit
• *Bamba® snack (Osem; approximately two thirds of a 1 oz.
(25 g) bag; 21 sticks of Bamba®) - for young infants
(<7 months), softened with 20 – 30 ml water or milk and
mixed with milk or with mashed or pureed fruit or vegetables
• Peanut soup
• Finely ground peanuts mixed into other foods such as yoghurt
*Other foods more customary to particular nations/cultures may
be substituted
Whole peanut is not recommended for introduction as this is a
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they are clinically reactive before initiating at-home
peanut introduction. Both such strategies were used in
the LEAP trial protocol.
 Adherence in the LEAP trial was excellent (92 %), with
infants randomized to consume peanut ingesting a
median of 7.7 g peanut protein (interquartile range:
6.7 – 8.8 g) per week during the first 2 years of the trial
compared with a median of 0 g in the avoidance group
(see Box 2 for examples of peanut-containing foods
used in the LEAP trial). Although the outcome of the
LEAP regimen was excellent, the study does not
address use of alternative doses of peanut protein,
minimal length of treatment necessary to induce the
tolerogenic effect, or potential risks of premature
discontinuation or sporadic feeding of peanut.choking hazard in children under the age of 4.
Box 1 Enrollment Criteria Used in the LEAP Study
Infants considered at “high risk” as defined by the LEAP study
criteria:
Egg allergy: Children with either –
1) A SPT wheal diameter ≥6 mm from exposure to raw hen’s
egg white and no history of previous egg tolerance,
or
2) A SPT wheal diameter ≥3 mm from exposure to
pasteurized hen’s egg white and allergic symptoms related to
exposure to hen’s egg.
Severe eczema: An eczematous rash that –
1) Requires application of topical creams, ointments, or both,
containing corticosteroids or calcineurin inhibitors, and that, if
the participant is <6 months of age, lasted for at least 12 of
30 days on 2 occasions, or, if the participant is >6 months of
age, lasted for at least 12 of 30 days on two occasions in the
last 6 months,
Or
2) Is currently or was previously graded ≥ 40 using the
modified SCORAD evaluation
Example of method of skin prick testing: used in the LEAP study
• SPTs to peanut should be performed in the presence of a
negative control and a positive histamine control.
• SPTs should be performed in duplicate, and the maximum
wheal diameter of the two SPTs should be calculated and
rounded up to the greatest whole millimeter
Of note, in the LEAP trial measurement of IgE to peanut resulted
in considerably higher rates of sensitization compared with skin
testing, which could lead to numerous unnecessary oral peanut
challenges.Rationale for evaluating and applying this policy
to a high-risk population
The LEAP trial demonstrates that early peanut introduc-
tion can be successfully carried out in a high-risk popu-
lation, such as the population defined in the LEAP trial.
However, without intervention by health care providers,
there is the potential that such high-risk infants will re-
main at risk for delayed introduction of solids and aller-
genic foods into their diet because of the widespread
belief that such foods may exacerbate eczema.
There will be more extensive guidelines in the near future
from the NIAID Working Group and EAACI Guidelines
Group with their multidisciplinary stakeholders. These
groups will consider all the available data and determine
whether there is sufficient evidence to apply prevention
strategies to the general population. However, engagement
of the primary care, allergy, and dermatology communities
to rapidly implement these findings and change the culture
of early feeding practices is essential, and the forthcoming
NIAID Working Group’s and EAACI Guidelines Group’s
documents will better clarify a best-practices approach.
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